Trials / Unknown
UnknownNCT03283228
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML. 2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.
Detailed description
1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients. 2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Cd11b and Cd56 markers | The expression of CD11b and CD56 in newly diadnosed cases of AML |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2018-12-01
- Completion
- 2019-10-01
- First posted
- 2017-09-14
- Last updated
- 2017-09-14
Source: ClinicalTrials.gov record NCT03283228. Inclusion in this directory is not an endorsement.